Search papers, labs, and topics across Lattice.
This paper introduces RELIABLE-BA, an evidential framework for multi-engine protein-ligand binding affinity prediction that addresses the limitations of traditional docking engines by incorporating context-aware reliability measures. By modeling each docking engine as an evidential expert and fusing their predictions while accounting for uncertainty and inter-engine disagreement, the authors achieve improved accuracy and uncertainty calibration on benchmark datasets. The framework not only enhances predictive performance but also enables a significant reduction in prediction error by up to 25% through reliable filtering of high-confidence protein-ligand pairs, marking a significant advancement in AI-driven drug discovery.
Uncertainty-aware predictions can cut binding affinity prediction errors by 25%, revolutionizing trust in AI-driven drug discovery.
Accurate protein-ligand binding affinity prediction is central to computational drug discovery, yet modern docking engines frequently disagree without indicating which prediction to trust. Consensus scoring and ensemble methods improve mean accuracy but treat all predictions identically without interpretable confidence measures or uncertainty decomposition, ignoring the chemical context of each protein-ligand pair. To address this limitation, we introduce RELIABLE-BA (RELIABiLity-aware Evidential fusion for Binding Affinity), an evidential framework for multi-engine binding affinity prediction. Our model comprises three steps: (1) modeling each engine as an evidential expert via Normal-Inverse-Gamma distributions, (2) scaling epistemic uncertainty through learned reliability from molecular context while preserving each expert's predictive mean, and (3) fusing experts through closed-form aggregation that captures both individual uncertainty and inter-engine disagreement. Experiments on the PDBBind and BDB2020+ benchmarks demonstrate competitive point prediction with substantially improved uncertainty calibration, and additional validation on the SARS-CoV-2 Mpro dataset and 5HT2A receptor demonstrates applicability to clinically relevant drug targets. Crucially, these uncertainty estimates enable reliable filtering of protein-ligand pairs, reducing prediction error by up to 25% when retaining only high-confidence pairs. To our knowledge, RELIABLE-BA is the first multi-engine binding affinity prediction framework to combine evidential fusion with context-dependent reliability, offering a principled path toward trustworthy AI-guided drug discovery. Our code is publicly available at https://github.com/yongchand/RELIABLE-BA.
